In recent trading, shares of Cboe Global Markets Inc (Symbol: CBOE) have crossed above the average analyst 12-month target price of $281.23, changing hands for $283.09/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra
In recent trading, shares of Cboe Global Markets Inc (Symbol: CBOE) have crossed above the average analyst 12-month target price of $281.23, changing hands for $283.09/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra
In recent trading, shares of Nova Ltd (Symbol: NVMI) have crossed above the average analyst 12-month target price of $480.33, changing hands for $485.43/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation
In recent trading, shares of Nova Ltd (Symbol: NVMI) have crossed above the average analyst 12-month target price of $480.33, changing hands for $485.43/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation
In recent trading, shares of Expeditors International of Washington, Inc. (Symbol: EXPD) have crossed above the average analyst 12-month target price of $140.77, changing hands for $141.97/share. When a stock reaches the target an analyst has set, the analyst logically has two w
In recent trading, shares of Expeditors International of Washington, Inc. (Symbol: EXPD) have crossed above the average analyst 12-month target price of $140.77, changing hands for $141.97/share. When a stock reaches the target an analyst has set, the analyst logically has two w
In recent trading, shares of Camtek Ltd (Symbol: CAMT) have crossed above the average analyst 12-month target price of $173.83, changing hands for $179.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati
In recent trading, shares of Camtek Ltd (Symbol: CAMT) have crossed above the average analyst 12-month target price of $173.83, changing hands for $179.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati
In recent trading, shares of Veeco Instruments Inc (Symbol: VECO) have crossed above the average analyst 12-month target price of $33.75, changing hands for $34.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
In recent trading, shares of Veeco Instruments Inc (Symbol: VECO) have crossed above the average analyst 12-month target price of $33.75, changing hands for $34.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
hapabapa Merck ( MRK ), operating as MSD outside the U.S. and Canada, on Wednesday said it will acquire clinical-stage biotech Terns Pharmaceuticals ( TERN ) in an all-cash deal valued at approximately $6.7 billion. Merck will pay $53.00 per share, representing a significant premium over Terns' recent trading average, as it seeks to integrate the promising leukemia candidate TERN-701 into its hema...
hapabapa Merck ( MRK ), operating as MSD outside the U.S. and Canada, on Wednesday said it will acquire clinical-stage biotech Terns Pharmaceuticals ( TERN ) in an all-cash deal valued at approximately $6.7 billion. Merck will pay $53.00 per share, representing a significant premium over Terns' recent trading average, as it seeks to integrate the promising leukemia candidate TERN-701 into its hematology portfolio. Following the announcement, Terns Pharmaceuticals ( TERN ) shares jumped 5.5% in premarket trading, hovering near the acquisition price as investors reacted to the definitive agreement. The transaction is expected to be accounted for as an asset acquisition and close in the second quarter of 2026, resulting in a charge of approximately $5.8 billion, or approximately $2.35 per share, included in both second-quarter and full-year 2026 GAAP and non-GAAP results, Merck ( MRK ) said in a statement . Merck ( MRK ) has been pursuing deals to strengthen its pipeline, with CEO Rob Davis spearheading a strategy to diversify the company's portfolio ahead of the 2028 patent expiration for its blockbuster cancer drug, Keytruda. Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns. The acquisition is subject to a majority of Terns’ stockholders tendering their shares in a tender offer that will be initiated by a subsidiary of Merck. “The acquisition of Terns builds on our growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia,” said Robert M. Davis , chairman and chief executive officer, Merck. “This transaction further diversifies and strengthens our position in oncology as we continue to look for opportunities to broaden our portfolio into other therapeutic areas.” More on Merck Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript Health Care Q4 Dividend Roundup: Merck ...
近日,由中国信息通信研究院(简称“中国信通院”)牵头,博通、腾讯、维谛、华为、谷歌、快手、中兴、BDC、阿里、超聚变等单位共同参与编制的IEEE《全球数据中心发展趋势报告》正式发布。该报告是IEEE-SA ODCI(Open Data Center Initiative,开放算力计划,简称ODCI)的重要研究成果之一,为全球算力产业发展提供重要参考与指引。(中国信通院)
近日,由中国信息通信研究院(简称“中国信通院”)牵头,博通、腾讯、维谛、华为、谷歌、快手、中兴、BDC、阿里、超聚变等单位共同参与编制的IEEE《全球数据中心发展趋势报告》正式发布。该报告是IEEE-SA ODCI(Open Data Center Initiative,开放算力计划,简称ODCI)的重要研究成果之一,为全球算力产业发展提供重要参考与指引。(中国信通院)